Clinical Trial

BIOSILITACE AS A DESENSITIZING AGENTIN HMI

Study acronym: BDAHMI
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Molar-Incisor Hypomineralization (MIH) is a qualitative enamel defect caused by systemic hypomineralization that affects one to four first permanent molars, and may or may not involve incisors. The clinical repercussions associated with MIH can be characterized by: painful hypersensitivity, post-eruptive fractures, rapid progression of caries lesions in newly erupted first permanent molars, difficulty in achieving effective anesthesia, aesthetic impairments, and patient fear and anxiety. To date, there is no consensus on the best treatment for sensitivity in teeth with MIH, thus managing sensitivity in these teeth remains a significant challenge. The aim of this study is to evaluate the effectiveness of a 10% Biosilicate® solution as a desensitizing agent in MIH teeth in children, compared to Fluoride varnish (Duraphat® Colgate, Brazil). Children aged 6 to 12 years will be selected for this study, with a total of 63 participants diagnosed with MIH, and a sensitivity score ≥2 on the SCASS scale. The children will be randomly divided into two groups (n=21): GI: Duraphat®, GII: Biosilicate®. Interventions will be performed once a week for 4 consecutive weeks, followed by 8 weeks of follow-up. The results will be subjected to statistical tests with a 95% confidence level (α = 0.05).
Trial Details
NCT Number NCT07080645
Lead Sponsor University of Sao Paulo
Collaborators: Conselho Nacional de Desenvolvimento Científico e Tecnológico
Conditions Sensitive Dentin, Hypomineralization Molar Incisor, Pain
Enrollment 42 participants
Start Date 2025-07-30
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-07-23